Insights

Innovative Nanotech Platform Nanomerics' proprietary Molecular Envelope Technology (MET) enhances drug delivery across various routes including oral, nasal, and crossing the blood-brain barrier, positioning the company as a leader in advanced nanomedicine solutions that can be customized for diverse therapeutic areas.

Pipeline and Collaborations With ongoing partnerships with NASDAQ-listed companies for oral drugs and Asian partners for nasal delivery, alongside developing its own products, Nanomerics offers multiple entry points for strategic alliances and licensing opportunities.

Market Expansion Potential Nanomerics has active projects targeting ophthalmic conditions and oncology, indicating opportunities to expand into specialized medical markets where nanotechnology can provide significant therapeutic advantages.

Recognition and Credibility Receiving the King’s Award for Enterprise 2024 in innovation underscores the company's leadership in pharmaceutical nanotechnology, providing a strong foundation for trust and credibility when engaging with new clients or investors.

Early-Stage Revenue and Growth While current revenue is modest, under $1 million, the company's innovative technology and strategic partnerships suggest high potential for market growth and expansion into new therapeutic areas, presenting sales opportunities in licensing, distribution, and joint development.

Similar companies to Nanomerics Ltd

Nanomerics Ltd Tech Stack

Nanomerics Ltd uses 8 technology products and services including Ahoy, Webpack, Module Federation, and more. Explore Nanomerics Ltd's tech stack below.

  • Ahoy
    Analytics
  • Webpack
    Development
  • Module Federation
    Development
  • Google Fonts API
    Font Scripts
  • Google Cloud
    Infrastructure As A Service
  • Sentry
    Issue Trackers
  • JSON-LD
    Javascript Frameworks
  • RequireJS
    Javascript Frameworks

Nanomerics Ltd's Email Address Formats

Nanomerics Ltd uses at least 1 format(s):
Nanomerics Ltd Email FormatsExamplePercentage
First.Last@nanomerics.comJohn.Doe@nanomerics.com
41%
First@nanomerics.comJohn@nanomerics.com
9%
First.Last@nanomerics.comJohn.Doe@nanomerics.com
41%
First@nanomerics.comJohn@nanomerics.com
9%

Frequently Asked Questions

Where is Nanomerics Ltd's headquarters located?

Minus sign iconPlus sign icon
Nanomerics Ltd's main headquarters is located at London, England ha1 3uj United Kingdom. The company has employees across 2 continents, including EuropeSouth America.

What is Nanomerics Ltd's official website and social media links?

Minus sign iconPlus sign icon
Nanomerics Ltd's official website is nanomerics.com and has social profiles on LinkedIn.

What is Nanomerics Ltd's NAICS code?

Minus sign iconPlus sign icon
Nanomerics Ltd's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Nanomerics Ltd have currently?

Minus sign iconPlus sign icon
As of April 2026, Nanomerics Ltd has approximately 7 employees across 2 continents, including EuropeSouth America. Key team members include Ceo: A. S.Chief Scientific Officer: I. F. U. D.Director Of Preclinical Research & Development: I. K.. Explore Nanomerics Ltd's employee directory with LeadIQ.

What industry does Nanomerics Ltd belong to?

Minus sign iconPlus sign icon
Nanomerics Ltd operates in the Pharmaceutical Manufacturing industry.

What technology does Nanomerics Ltd use?

Minus sign iconPlus sign icon
Nanomerics Ltd's tech stack includes AhoyWebpackModule FederationGoogle Fonts APIGoogle CloudSentryJSON-LDRequireJS.

What is Nanomerics Ltd's email format?

Minus sign iconPlus sign icon
Nanomerics Ltd's email format typically follows the pattern of First.Last@nanomerics.com. Find more Nanomerics Ltd email formats with LeadIQ.

When was Nanomerics Ltd founded?

Minus sign iconPlus sign icon
Nanomerics Ltd was founded in 2010.

Nanomerics Ltd

Pharmaceutical ManufacturingEngland, United Kingdom2-10 Employees

Nanomerics uses its world-leading pharmaceutical nanotechnology to develop new medicines faster, cheaper, and with dramatically reduced risk. 

Nanomerics proprietary technology boosts the activity of hydrophobic drugs and peptides by getting them where they need to be. This allows the creation of new medicines based on known drug compounds that now can be given in new ways and for new indications. 

Nanomerics’ Molecular Envelope Technology (MET) is applicable to a broad range of compounds and allows targeting of diseases via the oral and nasal route, delivery to the eye, and across the blood-brain-barrier. 

Nanomerics offers its medicines development capability and expertise to partners wanting to enable specific drugs, e.g. the company is currently working with a NSADAQ company on two oral products and an Asian company on nasal delivery. 

Nanomerics also develops its own nano-enabled medicines and has products targeting the ophthalmic market as well as oral medicines e.g. in the area of oncology. 

Its lead product is a peptide for the treatment of chronic pain. The endogenous peptide is already known to be efficacious and safe. Combination with the MET system creates a nano-enabled medicine that avoids some of the significant problems of current opioid drugs.

Section iconCompany Overview

Headquarters
London, England ha1 3uj United Kingdom
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2010
Employees
2-10

Section iconFunding & Financials

  • $1M

    Nanomerics Ltd's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1M

    Nanomerics Ltd's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.